(From left) Yuichiro Yazaki, Prof. Naohide Yamashita, Prof. Ki-Ming Lai, and Chairman Chun-You Pan
Immunocell therapy is a good news again! Following the Ministry of Health and Welfare's decision to liberalize the use of immune cells for a number of cancer clinical treatments, the domestic biomedical industry has introduced Japan's successful development of "DC (dendritic cell) cancer vaccine" and "super NK (natural killer) cell" preparation patented technology, so that Taiwan's cancer patients don't have to travel far from Japan to seek medical treatment.
Accumulating 22 types of cancers, more than 100,000 cancer patients have used the Japanese immune cell culture technology to transfer to Taiwan
In the past, because of regulatory restrictions, many Taiwanese cancer patients had to travel to Japan to receive autologous immune cell therapy, which was not only costly, but also a long way to travel with their illnesses. The newest addition to the lineup is a new, more robust, and more robust version of the original, which is now available in a variety of formats, including a new, more robust, and more robust version of the original.
The DC (dendritic cell) cancer vaccine therapy was developed at the University of Tokyo and has been used in more than 11,000 patients with 22 types of cancer in Japan, including pancreatic cancer, which is relatively ineffective with conventional anti-cancer treatments, colorectal cancer, which is the most prevalent cancer in the country, and lung cancer, which is the leading cancer in terms of the number of deaths.
Dendritic cell vaccine Command tower of immune cells in the body Directs the lymphocytes to attack the cancer cells
Dendritic cells bind to potent cancer antigens Command T Cells T Cells Cells Cells Cells that are directed by the dendritic cells to recognize cancer cells. strong> Make 'cold' tumors hot!
Professor Naohide Yamashita also believes that combining more precise tumor antigen and dendritic cell therapies in the future could also maximize the effectiveness of immune checkpoint inhibitors! Professor Naohide Yamashita pointed out that tumor immune checkpoint inhibitors are not effective against every tumor or all cancers, and one of the key issues is how many T-lymphocytes there are in the cancer tissue that are responsible for the attack! This is the difference between a "hot tumor" and a "cold tumor!
He illustrated this new concept of cancer immunotherapy by comparing sections of melanocytoma tissue with sections of pancreatic cancer tissue. He pointed out that the melanocytoma tissue section had many T cells, which is called a "hot tumor," whereas the pancreatic cancer section had almost no detectable T cells, which is called a "cold tumor. When an immune checkpoint inhibitor removes the brakes on T cells, hot tumors filled with T cells are easily cleared by activated T cells, but cold tumors do not respond because there are no T cells responsible for attack. In the future, he believes that the development of more precise and personalized antigen combinations, combined with dendritic therapies that allow tumors to go from cold to hot, will allow immune checkpoint inhibitors to be used to maximum effect!
In addition to the dendritic cell vaccine, Super NK cells have also been used in Japan in conjunction with chemotherapy and targeted therapies, and have been shown to have a positive effect on reducing side effects, decreasing pain, boosting immunity, increasing stamina, and killing cancer cells. Together with the dendritic cell vaccine, the company's two agents have been used in the treatment of more than 100,000 cancer patients in Japan.
Taiwan Cancer Foundation Executive Director, Wan Fang Hospital Cancer Center Director Professor Lai Ji-Ming pointed out that the immune cell therapy provided by the NK cells and so on, like after *** all kinds of armed forces, the formation of a sea of people to attack cancer cells. After the implementation of the special control measures, as long as through the orthodox medical institutions and specialized physicians, to formulate treatment plans, submit applications for clinical application, and have qualified culture and expansion equipment GTP laboratories to manufacture the cell products used, there will be a chance to pass the application, the treatment of cancer patients. This is a powerful shot in the arm for immune cell therapy, and we believe that immune cell therapy will flourish in the foreseeable future.
Join in and pay attention to your health every day! LINE@ ID:@ Subscribe to the Health Love LOHAS AV channel to read health knowledge more easily : /supply/article/39527 Keywords: Ministry of Health and Welfare, Bay Cancer Foundation, Wanfang Hospital, Cancer Center, Lai Kei-ming, Super NK cells.